https://www.nasdaq.com/press-release/anavex-life-sciences-to-present-at-the-h.c.-wainwright-virtual-bioconnect-2022
https://www.nasdaq.com/press-release/anavex-life-sciences-to-present-at-40th-annual-j.p.-morgan-healthcare-conference-2021
https://www.nasdaq.com/press-release/anavex-life-sciences-to-present-at-the-4th-annual-evercore-isi-healthconx-conference
https://www.nasdaq.com/press-release/anavex-life-sciences-provides-business-update-and-reports-fiscal-2021-year-end
https://www.nasdaq.com/press-release/anavex-life-sciences-to-announce-fiscal-2021-year-end-financial-results-on-wednesday
https://www.nasdaq.com/press-release/anavex-life-sciences-announces-participation-at-upcoming-lausanne-viii-workshop-panel
https://www.nasdaq.com/press-release/anavex-life-sciences-to-present-at-the-dawson-james-securities-6th-annual-conference
https://www.nasdaq.com/press-release/anavex-life-sciences-reports-data-review-by-the-independent-data-safety-monitoring-0
https://www.nasdaq.com/press-release/anavex-life-sciences-announces-participation-at-5th-pharma-pricing-reimbursement
https://www.nasdaq.com/press-release/anavex-life-sciences-announces-uplisting-to-the-nasdaq-global-select-marketr-2021-09
https://www.nasdaq.com/press-release/anavex-life-sciences-to-present-at-the-2021-cantor-virtual-global-healthcare
https://www.nasdaq.com/press-release/anavex-life-sciences-to-present-at-the-h.c.-wainwright-23rd-annual-global-investment
https://www.nasdaq.com/press-release/anavex-life-sciences-announces-publication-of-foundational-data-for-anavexr2-73-1
https://www.nasdaq.com/press-release/anavex-life-sciences-provides-business-update-and-reports-fiscal-2021-third-quarter
https://www.nasdaq.com/press-release/anavex-life-sciences-to-announce-fiscal-2021-third-quarter-financial-results-on
https://www.nasdaq.com/press-release/anavex-life-sciences-to-participate-in-the-btig-virtual-biotechnology-conference-2021
https://www.nasdaq.com/press-release/anavex-life-sciences-announces-anavexr2-73-blarcamesine-significantly-prevented-ab
https://www.nasdaq.com/press-release/anavex-life-sciences-announces-anavexr2-73-blarcamesine-improved-both-primary
https://www.nasdaq.com/press-release/anavex-life-sciences-announces-closing-of-%2450-million-registered-direct-offering-2021
https://www.nasdaq.com/press-release/anavex-life-sciences-announces-%2450-million-registered-direct-offering-2021-06-22
https://www.nasdaq.com/press-release/anavex-life-sciences-announces-anavexr2-73-blarcamesine-biomarker-correlated-with
https://www.nasdaq.com/press-release/anavex-life-sciences-reports-new-publication-in-medical-journal-elucidating-the
https://www.nasdaq.com/press-release/anavex-life-sciences-announces-exceeding-of-enrollment-target-for-the-precision
https://www.nasdaq.com/press-release/anavex-life-sciences-announces-notice-of-allowance-for-u.s.-patent-application
https://www.nasdaq.com/press-release/anavex-life-sciences-announces-appointment-of-ms-jiong-ma-phd-to-board-of-directors
https://www.nasdaq.com/press-release/anavex-life-sciences-reports-fiscal-2021-second-quarter-financial-results-and
https://www.nasdaq.com/press-release/anavex-life-sciences-announces-participation-at-precision-in-clinical-trials-0
https://www.nasdaq.com/press-release/anavex-life-sciences-to-announce-fiscal-2021-second-quarter-financial-results-and
https://www.nasdaq.com/press-release/anavex-life-sciences-appoints-former-fda-officer-as-senior-vice-president-for
https://www.nasdaq.com/press-release/anavex-life-sciences-to-present-at-the-b.-riley-securities-virtual-neuroscience
https://www.nasdaq.com/press-release/anavex-life-sciences-reports-the-results-of-review-by-the-independent-data-safety
https://www.nasdaq.com/press-release/anavex-life-sciences-to-present-at-the-20th-annual-needham-virtual-healthcare
https://www.nasdaq.com/press-release/anavex-life-sciences-announces-participation-at-upcoming-world-epa-evidence-pricing
https://www.nasdaq.com/press-release/anavex-life-sciences-reports-data-review-by-the-independent-data-safety-monitoring
https://www.nasdaq.com/press-release/anavex-life-sciences-reports-anavexr2-73-blarcamesine-featured-as-a-disease-modifying
https://www.nasdaq.com/press-release/anavex-life-sciences-to-present-at-the-h.c.-wainwright-global-life-sciences
https://www.nasdaq.com/press-release/anavex-life-sciences-announces-participation-at-upcoming-worldwide-national
https://www.nasdaq.com/press-release/anavex-life-sciences-announces-participation-at-precision-in-clinical-trials-virtual
https://www.nasdaq.com/press-release/anavex-life-sciences-to-present-at-the-10th-annual-svb-leerink-global-healthcare
https://www.nasdaq.com/press-release/anavex-life-sciences-reports-fiscal-2021-first-quarter-financial-results-and-business
https://www.nasdaq.com/press-release/anavex-life-sciences-to-announce-fiscal-2021-first-quarter-financial-results-and
https://www.nasdaq.com/press-release/anavex-life-sciences-receives-michael-j.-fox-foundation-grant-for-clinical-study-of
https://www.nasdaq.com/press-release/anavex-life-sciences-to-present-at-the-h.c.-wainwright-virtual-bioconnect-conference
https://www.nasdaq.com/press-release/anavex-life-sciences-reports-fiscal-2020-year-end-financial-results-and-clinical
https://www.nasdaq.com/press-release/anavex-life-sciences-to-announce-fiscal-2020-year-end-financial-results-december-28th
https://www.nasdaq.com/press-release/anavex-life-sciences-announces-webinar-on-rett-syndrome-and-anavexr2-73-blarcamesine
https://www.nasdaq.com/press-release/anavex-life-sciences-announces-anavexr2-73-blarcamesine-meets-primary-and-secondary
https://www.nasdaq.com/press-release/anavex-life-sciences-announces-notice-of-allowance-for-u.s.-patent-application-with
https://www.nasdaq.com/press-release/anavex-life-sciences-to-present-at-the-evercore-isi-3rd-annual-healthconx-conference
https://www.nasdaq.com/press-release/proof-of-concept-controlled-phase-2-clinical-trial-data-evaluating-anavexr2-73
https://www.nasdaq.com/press-release/anavex-life-sciences-announces-positive-results-from-proof-of-concept-controlled
https://www.nasdaq.com/press-release/anavex-life-sciences-announces-completion-of-anavexr2-73-blarcamesine-u.s.-phase-2
https://www.nasdaq.com/press-release/anavex-life-sciences-to-present-at-upcoming-global-healthcare-conferences-2020-09-08
https://www.nasdaq.com/press-release/anavex-life-sciences-announces-commitment-for-financial-investment-by-shake-it-up
https://www.nasdaq.com/press-release/anavex-life-sciences-reports-fiscal-2020-third-quarter-financial-results-and-provides
https://www.nasdaq.com/press-release/anavex-life-sciences-receives-tga-special-access-scheme-approval-for-anavexr2-73
https://www.nasdaq.com/press-release/anavex-life-sciences-to-announce-fiscal-2020-third-quarter-financial-results-on
https://www.nasdaq.com/press-release/anavex-life-sciences-announces-first-participant-enrolled-in-phase-1-study-of
https://www.nasdaq.com/press-release/anavex-life-sciences-announces-first-patient-dosed-in-excellence-phase-2-3-clinical
https://www.nasdaq.com/press-release/anavex-life-sciences-announces-exceeding-of-enrollment-target-for-the-anavexr2-73
https://www.nasdaq.com/press-release/anavex-life-sciences-receives-regulatory-approval-from-health-canada-and-uk-mhra
https://www.nasdaq.com/press-release/anavex-life-sciences-announces-initiation-of-first-in-human-phase-1-study-of-anavexr3
https://www.nasdaq.com/press-release/anavex-life-sciences-reports-fiscal-2020-second-quarter-financial-results-and
https://www.nasdaq.com/press-release/anavex-life-sciences-to-announce-fiscal-2020-second-quarter-financial-results-on
https://www.nasdaq.com/press-release/anavex-life-sciences-announces-publication-of-clinical-data-for-anavexr2-73
https://www.nasdaq.com/press-release/anavex-life-sciences-provides-update-on-clinical-program-development-as-response-to
https://www.nasdaq.com/press-release/anavex-life-sciences-to-webcast-2020-annual-meeting-of-shareholders-2020-03-23
https://www.nasdaq.com/press-release/anavex-life-sciences-announces-publication-of-foundational-data-for-anavexr2-73-0
https://www.nasdaq.com/press-release/anavex-life-sciences-reports-fiscal-2020-first-quarter-financial-results-and-provides
https://www.nasdaq.com/press-release/anavex-life-sciences-to-present-and-participate-in-a-panel-at-the-2020-bio-ceo
https://www.nasdaq.com/press-release/anavex-life-sciences-announces-fast-track-designation-granted-by-u.s.-fda-for
https://www.nasdaq.com/press-release/anavex-life-sciences-to-announce-fiscal-2020-first-quarter-financial-results-on
https://www.nasdaq.com/press-release/anavex-life-sciences-announces-achievement-of-enrollment-target-for-the-anavexr2-73
https://www.nasdaq.com/press-release/anavex-life-sciences-issued-new-u.s.-patent-for-anavexr2-73-treatment-of
https://www.nasdaq.com/press-release/anavex-life-sciences-reports-fiscal-year-2019-financial-results-and-provides-clinical
https://www.nasdaq.com/press-release/anavex-life-sciences-to-announce-fiscal-2019-year-end-financial-results-on-monday
https://www.nasdaq.com/press-release/anavex-life-sciences-presents-anavexr2-73-blarcamesine-data-at-12th-clinical-trials
https://www.nasdaq.com/press-release/anavex-life-sciences-receives-rare-pediatric-disease-designation-from-fda-for
https://www.nasdaq.com/press-release/anavex-life-sciences-announces-publication-of-foundational-data-for-anavexr2-73
https://www.nasdaq.com/press-release/anavex-life-sciences-announces-attention-ad-anavexr2-73-extension-clinical-study-in
https://www.nasdaq.com/press-release/anavex-life-sciences-issued-new-u.s.-patent-for-composition-of-matter-covering
https://www.nasdaq.com/press-release/anavex-life-sciences-presented-at-the-6th-annual-european-rett-syndrome-conference
https://www.nasdaq.com/press-release/anavex-life-sciences-to-present-at-the-2019-cantor-fitzgerald-global-healthcare
https://www.nasdaq.com/press-release/anavex-life-sciences-to-present-at-the-ladenburg-thalmann-2019-healthcare-conference
https://www.nasdaq.com/press-release/anavex-life-sciences-announces-preliminary-clinical-efficacy-data-of-its-u.s.-phase-2
https://www.nasdaq.com/press-release/anavex-life-sciences-presents-data-anavexr2-73-alzheimers-disease-american-society
https://www.nasdaq.com/press-release/anavex-life-sciences-announces-first-patient-dosed-phase-2-clinical-trial-anavexr2-73
https://www.nasdaq.com/press-release/anavex-life-sciences-present-31st-annual-roth-conference-2019-2019-04-21
